The combination of disitamab vedotin and toripalimab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive locally advanced or metastatic urothelial carcinoma compared with standard chemotherapy. A 64% reduction in the risk of disease progression and a 46% reduction in the risk of death were achieved in the phase 3 study RC48-C016. Median overall survival was 31.5 months with combination therapy versus 16.9 months with chemotherapy. The objective response rate was 76.1% in the disitamab vedotin and toripalimab arm, while it was 50.2% in the chemotherapy arm. Treatment was well tolerated, with fewer patients experiencing serious adverse events (55.1% vs. 86.9% with chemotherapy). This combination represents a potentially new standard of care for patients with HER2-expressing urothelial carcinoma in the first line of treatment[1][2][3][4][5][6].